

Appendix A: Guideline Development Group Declarations of Interest

A.1 Guideline Development Group Declarations of Interest [2004]

The following people have declared no competing interests in relation to the guideline: Keith MacDermott; Mary Sanderson; Malcolm Thomas; Stephen Wright.

MN (Joe) Asghar is employed by the Department of Health and has previously worked for 3M Pharmaceuticals as a member of their professional advisory committee.

James Dalrymple is a member of the Primary Care Society of Gastroenterology, attending the annual meeting supported by Wyeth; he was a member of the Norfolk Dyspepsia Guidelines Group 1999 & 2001.

Brendan Delaney has received speaking honoraria from AstraZeneca UK, Astra-Zeneca Canada, Astra-Zeneca Sweden, AxCanPharma Canada, Eisai, but has never held a consultancy role; he has also received research grants in dyspepsia from the Medical Research Council and is supported by an NHS R&D Primary Care Career Scientist Award.

James Mason has previously received academic grants, fees and expenses for research and consultancy work from the UK Department of Health, medical charities and from the pharmaceutical industry who manufacture treatments discussed in this report.

Paul Moayyedi has received funding from the Medical Research Council; is a member of Gastrointestinal section of the British Society of Gastroenterology; is acting coordinating editor for the Cochrane upper gastrointestinal and pancreatic diseases group; is an Independent Medical Advisor for Astra-Zeneca and has received speakers' fees from AstraZeneca, Wyeth, Byk Gulden, Eisai and Abbott.

Anan Raghunath has attended occasional Primary Care Advisory meetings with AstraZeneca; he is also studying for a PhD on Use of Proton Pump Inhibitors in General Practice at the University of Durham.

Robert Walt produced the first and revised BSG Dyspepsia Guidelines; has received academic support for education and research from GlaxoSmithKline, Astra, Janssen, Wyeth, Searle, MSD; and has no formal consultancy at present or in the past 5 years.

A.2 Guideline Development Group Declarations of Interest [update 2014]

GDG Member	Interest declared	Type of interest	Decision taken
Hugh Barr	Chief Investigator for NIHR Barrett's Oesophagus Surveillance Study	Non-personal pecuniary, specific	Declare and participate
	Advise patient support	Personal non-	Declare and

GDG Member	Interest declared	Type of interest	Decision taken
	groups for dyspepsia and heartburn	pecuniary	participate
John deCaestecker	Regional Advisor, Leicestershire, Northamptonshire & Rutland	Non-personal pecuniary, specific	Declare and participate
	Chair on AspECT (trial on the effect of aspirin and esomprazole on the development of cancer in people with Barrett's)	Non-personal pecuniary, specific	Declare and participate
	Chief Investigator on BRIDE (study in Barrett's with HGD/early cancer)	Non-personal pecuniary, specific	Declare and participate
	Steering member of EAGLE (genetic trial)	Non-personal pecuniary, non-specific	Declare and participate
	Receives a fee for advice and statements for OTC Zantac	Personal pecuniary, non-specific	Declare and participate
	Part of steering committee for HEAT (trial of <i>H pylori</i> in aspirin users)	Non-personal pecuniary, non-specific	Declare and participate
Mark Follows	Contributed to the Map of Medicine for Dyspepsia	Personal pecuniary, non-specific	Declare and participate
Alex Ford	Part of steering committee for HEAT (trial of <i>H pylori</i> in aspirin users)	Non-personal pecuniary, non-specific	Declare and participate
Ann Harding	Summariser in GP Practice	Personal pecuniary, non-specific	Declare and participate
Janusz Jankowski	Chair of Barrett's Dysplasia Cancer Task force	Personal non-pecuniary, non-specific	Declare and participate
	Member of Benign Barrett's and Cancer Task force	Personal non-pecuniary, non-specific	Declare and participate
	Chief Investigator for Chopin (genetic trial)	Non-personal pecuniary, non-specific	Declare and participate
	Chief Investigator on AspECT (effect of aspirin and esomprazole on the development of cancer in people with BO)	Non-personal pecuniary, specific	Declare and withdraw when making recommendations on the effectiveness of PPIs for severe oesophagitis

GDG Member	Interest declared	Type of interest	Decision taken
	Part of the local Commissioning Board for East Midlands	Non-personal pecuniary, specific	Declare and participate
Mimi McCord	Lay Member on panel advising Department of Health campaign for oesophagogastric cancer	Personal non-pecuniary, non-specific	Declare and participate
	Chairman of Heartburn Cancer Awareness & Support	Personal non-pecuniary, non-specific	Declare and participate
Cliona McNulty (Co-opted expert)	Lead the primary care group that writes the HPE primary care guidance including the management of <i>Helicobacter pylori</i> .	Non personal pecuniary, specific	Declare and participate
Marco Novelli (Co-opted expert)	Private practice for Independent Histopathology Services	Personal pecuniary, non-specific	Declare and participate
	A trustee for a patient charity	Personal non-pecuniary	Declare and participate